Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IQCJ-SCHIP1 is a protein produced via read-through transcription between the IQCJ and SCHIP1 genes, resulting in a fusion product characterized by motifs from both parental genes, including an IQ calmodulin-binding domain and a coiled-coil domain[3][4][5]. It is highly expressed in the brain and localizes to cytoplasmic and actin-rich sites, including axon initial segments and nodes of Ranvier[1][3]. IQCJ-SCHIP1 interacts with various neural cytoskeletal and channel proteins, such as ankyrin-G, βIV-spectrin, and Kv7.2/3, which suggests a key scaffolding and organizational role in neural architecture[1][2]. Although alterations in its function can modify axonal and nodal shape, it is not required for the accumulation of key nodal proteins[1]. There is currently no known role for IQCJ-SCHIP1 as a therapeutic drug target, nor are there established disease associations, clinical biomarkers, or safety concerns[1][3][7].
Not applicable; no drugs currently target this protein directly
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IQ motif containing J-schwannomin interacting protein 1 read-through transcript (IQCJ-SCHIP1) (IQCJ-SCHIP1).